SCHEMBL20511568

SCHEMBL20511568

CC(OC(=O)C(C)OC(=O)C(C)OC(=O)C(C)OC(=O)CCC(=O)O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 2/20 0.39
KDM6B O15054 1/20 0.39
KDM5C P41229 1/20 0.39
PHF8 Q9UPP1 1/20 0.39
KDM2A Q9Y2K7 1/20 0.39
CYP1A2 P05177 1/20 0.38
LMNA P02545 5/20 0.35
ALKBH5 Q6P6C2 1/20 0.35
SUCNR1 Q9BXA5 1/20 0.35
FOLH1 Q04609 7/20 0.34
GABRP O00591 2/20 0.33
GABRD O14764 2/20 0.33
GABRA1 P14867 2/20 0.33
GABRB1 P18505 2/20 0.33
GABRG2 P18507 2/20 0.33
GABRB3 P28472 2/20 0.33
GABRA5 P31644 2/20 0.33
GABRA3 P34903 2/20 0.33
GABRA2 P47869 2/20 0.33
GABRB2 P47870 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL935213 0.92 EGLN1 (0.45) EGLN1KDM6BKDM5CPHF8KDM2A
SCHEMBL15066277 0.87 EGLN1 (0.38) EGLN1KDM6BKDM5CPHF8KDM2A
Ethylene Glycol SCHEMBL2424946 0.86 EGLN1 (0.41) EGLN1KDM6BKDM5CPHF8KDM2A
SCHEMBL7110445 0.85 LMNA (0.40) EGLN1KDM6BKDM5CPHF8KDM2A
SCHEMBL2608669 0.85 LMNA (0.40) EGLN1KDM6BKDM5CPHF8KDM2A
SCHEMBL20061759 0.85 ALDH1A1 (0.41) CYP1A2LMNAMMP1MMP2MMP3
SCHEMBL20061760 0.85 ALDH1A1 (0.41) CYP1A2LMNAMMP1MMP2MMP3
SCHEMBL9555136 0.83 CA1 (0.38) CYP1A2LMNAFOLH1MMP1MMP2
1,4-Butanediol SCHEMBL2420738 0.83 GPR84 (0.43) EGLN1KDM6BKDM5CPHF8KDM2A
SCHEMBL15960972 0.82 MGAM (0.36) FOLH1MMP1MMP2MMP3MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092745-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2024-03-21 US disclosed
US-11548861-B2 Drugs and compositions for the treatment of ocular disorders Graybug Vision, Inc. (US) 2023-01-10 US disclosed
EP-3600324-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2020-02-05 EP disclosed
US-20200031783-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2020-01-30 US disclosed
WO-2018175922-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS Graybug Vision, Inc. (US) 2018-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031783-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS PDE6C, PDE6A, PDE6D EGLN1 1302/4885KDM6B 3228/4885KDM5C 4367/4885
US-11548861-B2 Drugs and compositions for the treatment of ocular disorders PDE6C, PDE6A, PDE6D EGLN1 1302/4885KDM6B 3228/4885KDM5C 4367/4885
US-20240092745-A1 DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS PDE6C, PDE6A, PDE6D EGLN1 1302/4885KDM6B 3228/4885KDM5C 4367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.